Nirianne Marie Palacpac

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9143329/publications.pdf

Version: 2024-02-01

59 papers

2,420 citations

236925 25 h-index 223800 46 g-index

62 all docs

62 docs citations

times ranked

62

2850 citing authors

#	Article	IF	CITATIONS
1	Characterization of a Plasmodium falciparum PHISTc protein, PF3D7_0801000, in blood-stage malaria parasites. Parasitology International, 2021, 80, 102240.	1.3	2
2	Ex vivo susceptibility of Plasmodium falciparum to antimalarial drugs in Northern Uganda. Parasitology International, 2021, 81, 102277.	1.3	9
3	Assessment of Mixed Plasmodium falciparumÂsera5 Infection in Endemic Burkitt Lymphoma: A Case-Control Study in Malawi. Cancers, 2021, 13, 1692.	3.7	9
4	Evidence of Artemisinin-Resistant Malaria in Africa. New England Journal of Medicine, 2021, 385, 1163-1171.	27.0	413
5	First-in-human randomised trial and follow-up study of Plasmodium falciparum blood-stage malaria vaccine BK-SE36 with CpG-ODN(K3). Vaccine, 2020, 38, 7246-7257.	3.8	19
6	Global Repertoire of Human Antibodies Against Plasmodium falciparum RIFINs, SURFINs, and STEVORs in a Malaria Exposed Population. Frontiers in Immunology, 2020, 11, 893.	4.8	15
7	Recovery and stable persistence of chloroquine sensitivity in Plasmodium falciparum parasites after its discontinued use in Northern Uganda. Malaria Journal, 2020, 19, 76.	2.3	23
8	Characteristic features of the SERA multigene family in the malaria parasite. Parasites and Vectors, 2020, 13, 170.	2.5	15
9	Malaria vaccines: facing unknowns. F1000Research, 2020, 9, 296.	1.6	8
10	The N-Terminal Region of Plasmodium falciparum MSP10 Is a Target of Protective Antibodies in Malaria and Is Important for PfGAMA/PfMSP10 Interaction. Frontiers in Immunology, 2019, 10, 2669.	4.8	13
11	Bifunctional activity of fused Plasmodium falciparum orotate phosphoribosyltransferase and orotidine 5′-monophosphate decarboxylase. Parasitology International, 2018, 67, 79-84.	1.3	4
12	Comprehensive analysis of antibody responses to Plasmodium falciparum erythrocyte membrane protein 1 domains. Vaccine, 2018, 36, 6826-6833.	3.8	19
13	Artemisinin <i>-</i> Resistant <i>Plasmodium falciparum</i> with High Survival Rates, Uganda, 2014–2016. Emerging Infectious Diseases, 2018, 24, 718-726.	4.3	104
14	Antibody profiles to wheat germ cell-free system synthesized Plasmodium falciparum proteins correlate with protection from symptomatic malaria in Uganda. Vaccine, 2017, 35, 873-881.	3.8	55
15	Immune evasion of Plasmodium falciparum by RIFIN via inhibitory receptors. Nature, 2017, 552, 101-105.	27.8	118
16	A possible origin population of pathogenic intestinal nematodes, Strongyloides stercoralis, unveiled by molecular phylogeny. Scientific Reports, 2017, 7, 4844.	3.3	62
17	Absence of in vivo selection for K13 mutations after artemether–lumefantrine treatment in Uganda. Malaria Journal, 2017, 16, 23.	2.3	24
18	Identification of Plasmodium falciparum reticulocyte binding protein homologue 5-interacting protein, PfRipr, as a highly conserved blood-stage malaria vaccine candidate. Vaccine, 2016, 34, 5612-5622.	3.8	25

#	Article	IF	Citations
19	Application of a cell microarray chip system for accurate, highly sensitive and rapid diagnosis for malaria in Uganda. Scientific Reports, 2016, 6, 30136.	3.3	24
20	Immunogenicity and protection from malaria infection in BK-SE36 vaccinated volunteers in Uganda is not influenced by HLA-DRB1 alleles. Parasitology International, 2016, 65, 455-458.	1.3	2
21	Antibody titres and boosting after natural malaria infection in BK-SE36 vaccine responders during a follow-up study in Uganda. Scientific Reports, 2016, 6, 34363.	3.3	15
22	A privileged mentee. Parasitology International, 2015, 64, xx.	1.3	0
23	Preclinical Studies on a New Vaccine Formulation of BK-SE36, a Malaria Vaccine Candidate. Juntendo Medical Journal, 2015, 61, 360-369.	0.1	3
24	Hematological and Biochemical Data Obtained in Rural Northern Uganda. International Journal of Environmental Research and Public Health, 2014, 11, 4870-4885.	2.6	4
25	Generation of Rodent Malaria Parasites with a High Mutation Rate by Destructing Proofreading Activity of DNA Polymerase l'. DNA Research, 2014, 21, 439-446.	3.4	16
26	Protective Epitopes of the Plasmodium falciparum SERA5 Malaria Vaccine Reside in Intrinsically Unstructured N-Terminal Repetitive Sequences. PLoS ONE, 2014, 9, e98460.	2.5	38
27	Plasmodium falciparum mitochondrial genetic diversity exhibits isolation-by-distance patterns supporting a sub-Saharan African origin. Mitochondrion, 2013, 13, 630-636.	3.4	15
28	Within-population genetic diversity of Plasmodium falciparum vaccine candidate antigens reveals geographic distance from a Central sub-Saharan African origin. Vaccine, 2013, 31, 1334-1339.	3.8	25
29	Association of naturally acquired IgG antibodies against Plasmodium falciparum serine repeat antigen-5 with reduced placental parasitemia and normal birth weight in pregnant Ugandan women: A pilot study. Parasitology International, 2013, 62, 237-239.	1.3	9
30	Endemic Burkitt lymphoma is associated with strength and diversity of Plasmodium falciparum malaria stage-specific antigen antibody response. Blood, 2013, 122, 629-635.	1.4	31
31	Phase 1b Randomized Trial and Follow-Up Study in Uganda of the Blood-Stage Malaria Vaccine Candidate BK-SE36. PLoS ONE, 2013, 8, e64073.	2.5	73
32	Plasmodium cynomolgi genome sequences provide insight into Plasmodium vivax and the monkey malaria clade. Nature Genetics, 2012, 44, 1051-1055.	21.4	172
33	Geographic differentiation of polymorphism in the Plasmodium falciparum malaria vaccine candidate gene SERA5. Vaccine, 2012, 30, 1583-1593.	3.8	28
34	Gibberellin Biosynthetic Inhibitors Make Human Malaria Parasite Plasmodium falciparum Cells Swell and Rupture to Death. PLoS ONE, 2012, 7, e32246.	2.5	7
35	The Plasmodium Apicoplast Genome: Conserved Structure and Close Relationship of P. ovale to Rodent Malaria Parasites. Molecular Biology and Evolution, 2012, 29, 2095-2099.	8.9	42
36	Antibodies reactive to <i>Plasmodium falciparum</i> serine repeat antigen in children with Burkitt lymphoma from Ghana. International Journal of Cancer, 2012, 130, 1908-1914.	5.1	10

#	Article	IF	Citations
37	Plasmodium falciparum serine repeat antigen 5 (SE36) as a malaria vaccine candidate. Vaccine, 2011, 29, 5837-5845.	3.8	38
38	Clues to Evolution of the SERA Multigene Family in 18 Plasmodium Species. PLoS ONE, 2011, 6, e17775.	2.5	37
39	Recent increase of genetic diversity in Plasmodium vivax population in the Republic of Korea. Malaria Journal, 2011, 10, 257.	2.3	14
40	Concatenated mitochondrial DNA of the coccidian parasite Eimeria tenella. Mitochondrion, 2011, 11, 273-278.	3.4	41
41	Spontaneous Mutations in the <i>Plasmodium falciparum</i> Sarcoplasmic/ Endoplasmic Reticulum Ca ²⁺ -ATPase (PfATP6) Gene among Geographically Widespread Parasite Populations Unexposed to Artemisinin-Based Combination Therapies. Antimicrobial Agents and Chemotherapy, 2011, 55. 94-100.	3.2	23
42	Serologic Markers in Relation to Parasite Exposure History Help to Estimate Transmission Dynamics of Plasmodium vivax. PLoS ONE, 2011, 6, e28126.	2.5	26
43	Lineage-specific positive selection at the merozoite surface protein 1 (msp1) locus of Plasmodium vivax and related simian malaria parasites. BMC Evolutionary Biology, 2010, 10, 52.	3.2	24
44	Plasmodium falciparum Accompanied the Human Expansion out of Africa. Current Biology, 2010, 20, 1283-1289.	3.9	121
45	Divergence of the Mitochondrial Genome Structure in the Apicomplexan Parasites, Babesia and Theileria. Molecular Biology and Evolution, 2010, 27, 1107-1116.	8.9	91
46	Limited Polymorphism of the Plasmodium vivax Merozoite Surface Protein 1 Gene in Isolates from Turkey. American Journal of Tropical Medicine and Hygiene, 2010, 83, 1230-1237.	1.4	16
47	Evidences of protection against blood-stage infection of Plasmodium falciparum by the novel protein vaccine SE36. Parasitology International, 2010, 59, 380-386.	1.3	61
48	Plasmodium vivax serine repeat antigen (SERA) multigene family exhibits similar expression patterns in independent infections. Molecular and Biochemical Parasitology, 2006, 150, 353-358.	1.1	17
49	Human malaria parasite orotate phosphoribosyltransferase: functional expression, characterization of kinetic reaction mechanism and inhibition profile. Molecular and Biochemical Parasitology, 2004, 134, 245-255.	1.1	52
50	Developmental-stage-specific triacylglycerol biosynthesis, degradation and trafficking as lipid bodies in Plasmodium falciparum-infected erythrocytes. Journal of Cell Science, 2004, 117, 1469-1480.	2.0	70
51	Evidence that Plasmodium falciparum diacylglycerol acyltransferase is essential for intraerythrocytic proliferation. Biochemical and Biophysical Research Communications, 2004, 321, 1062-1068.	2.1	29
52	Lipid metabolism in Plasmodium falciparum-infected erythrocytes: possible new targets for malaria chemotherapy. Microbes and Infection, 2003, 5, 545-552.	1.9	49
53	Plant cultured cells expressing human beta 1,4-galactosyltransferase secrete glycoproteins with galactose-extended N-linked glycans. Glycobiology, 2003, 13, 199-205.	2.5	48
54	Serine Repeat Antigen (SERA5) Is Predominantly Expressed among the SERA Multigene Family of Plasmodium falciparum, and the Acquired Antibody Titers Correlate with Serum Inhibition of the Parasite Growth. Journal of Biological Chemistry, 2002, 277, 47533-47540.	3.4	89

#	Article	IF	CITATIONS
55	Plasmodium falciparum Phospholipase C Hydrolyzing Sphingomyelin and Lysocholinephospholipids Is a Possible Target for Malaria Chemotherapy. Journal of Experimental Medicine, 2002, 195, 23-34.	8.5	73
56	In Vivo Conversion of a Glycan to Human Compatible Type by Transformed Tobacco Cells. Biochemical and Biophysical Research Communications, 2001, 289, 553-557.	2.1	26
57	Structures of N-Linked Oligosaccharides of Glycoproteins from Tobacco BY2 Suspension Cultured Cells. Bioscience, Biotechnology and Biochemistry, 1999, 63, 35-39.	1.3	21
58	Clues to Evolution of the SERA Multigene Family in the Genus Plasmodium. , 0, , .		1
59	Meta-Analysis of Human Antibodies Against Plasmodium falciparum Variable Surface and Merozoite Stage Antigens. Frontiers in Immunology, 0, 13, .	4.8	1